RT Journal Article
SR Electronic
T1 Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.16.21260079
DO 10.1101/2021.07.16.21260079
A1 Yannick Galipeau
A1 Vinayakumar Siragam
A1 Geneviève Laroche
A1 Erika Marion
A1 Matthew Greig
A1 Michaeline McGuinty
A1 Ronald A Booth
A1 Yves Durocher
A1 Miroslava Cuperlovic-Culf
A1 Steffany A.L. Bennett
A1 Angela M. Crawley
A1 Patrick M. Giguère
A1 Curtis Cooper
A1 Marc-André Langlois
YR 2021
UL http://medrxiv.org/content/early/2021/07/18/2021.07.16.21260079.abstract
AB Antibodies raised against highly prevalent human seasonal coronaviruses (sCoVs), which are responsible for the common cold, are known to cross-react with SARS-CoV-2 antigens. This cross-reactivity prompts questions about their protective role against SARS-CoV-2 infections and COVID-19 disease severity. However, the relationship between sCoV exposure and SARS-CoV-2 correlates of protection have not been clearly identified. Here we performed a cross-sectional analysis of cross-reactivity and cross-neutralization to three SARS-CoV-2 antigens using pre-pandemic serum from four different groups: pediatrics and adolescents (<21 yrs of age), persons 21 to 70 yrs of age, persons older than 70 yrs of age, and persons living with HCV or HIV. We find that antibody cross-reactivity to SARS-CoV-2 antigens varied between 1.6% and 15.3% depending on the cohort and the isotype-antigen pair analyzed. We also demonstrate a broad range of neutralizing activity (0-45%) in pre-pandemic serum that interferes with SARS-CoV-2 spike attachment to ACE2. While the abundance of sCoV antibodies did not directly correlate with neutralization efficiency, by using machine learning methodologies, we show that neutralizing activity is rather dependent on the latent variables related to the pattern ratios of sCoVs antibodies presented by each person. These were independent of age or sex, and could be accurately predicted by comparing the relative ratios of IgGs in sera directed to NL63, 229E, HKU-1, and OC43 spike proteins. More specifically, we identified antibodies to NL63 and OC43 as being the two most important predictors of latent variables responsible for protection, and 229E as being the least weighted. Our data support that exposure to sCoVs triggers various cellular and immune responses that influence the efficiency of SARS-CoV-2 spike binding to ACE2, and may impact COVID-19 disease severity through various other latent variables. Graphical abstractCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialnoneFunding StatementThis study was supported in part by a COVID-19 Rapid Response grant by the Canadian Institute of Health Research (CIHR) and by a grant supplement by the Canadian Immunity Task Force (CITF) to M-A Langlois and by the National Research Council of Canada Collaborative R&D Initiative Pandemic Response Challenge Program Grant to SAL Bennett and M Cuperlovic-Culf (PR031-1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of human samples for this study was approved by the University of Ottawa Ethics Review Board: Certificates H-04-20-5727, H-04-21-6643 and H-07-20-6009.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the study raw data will be made publicly available upon request.